Skip to main navigation Skip to search Skip to main content

Artificial intelligence to improve the detection and risk stratification of acute pulmonary embolism (AID-PE): protocol for a pragmatic quasi-experimental comparator study

Samuel George Sinclair Gunning, Joseph Page, Jennifer Rossdale, Pia Frances Pemberton Charters, Benjamin Hudson, Stephen Lyen, Robert Mackenzie Ross, Annette Seatter, Jonathan W. Bartlett, Lisa Austin, Gareth Myring, Hugh McLeod, Paul Mitchell, Darryl Stimpson, Andrew Cookson, Jay Suntharalingam, Jonathan Carl Luis Rodrigues

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction Pulmonary embolism (PE) is a potentially fatal condition requiring timely diagnosis and treatment. CT pulmonary angiography (CTPA) is the gold standard for diagnosis and indicates PE severity through radiological markers of right heart strain. However, accurate interpretation and communication of these findings is often suboptimal in real-world practice. Artificial intelligence (AI) could alleviate pressure on radiology services by supporting PE identification, risk stratification and worklist prioritisation. Before widespread adoption, AI tools must be rigorously validated for diagnostic accuracy, safety and clinical impact. Methods and analysis This pragmatic single-centre, non-randomised quasi-experimental study will evaluate the diagnostic accuracy, feasibility, and clinical-cost impact of AI-assisted PE detection and risk stratification using AIDOC and IMBIO software. We will recruit two consecutive cohorts of adult patients undergoing CTPAs for suspected PE: a comparator cohort (12 months pre-AI implementation) and an intervention cohort (12 months post-AI implementation). AI will be applied retrospectively to the comparator cohort, while in the intervention cohort, radiologists will have contemporaneous access to the AI’s interpretation of CTPA images. A subset of retrospective scans, both PE-positive and PE-negative, will undergo expert thoracic radiologist review to establish a reference standard. Data on patient demographics, clinical management and outcomes will be collected. Clinical management pathways and patient outcomes will be compared between cohorts to assess AI’s influence on acute PE management. Health economic modelling will assess the cost-effectiveness of integrating AI technology within the diagnostic workflow of acute PE. Ethics and dissemination This study was approved by the UK Healthcare Research authority (IRAS 311735, 10 May 2023). Ethical approval was granted by West of Scotland Research Ethics Service (23/WS/0067, 3 May 2023). Results will be shared with stakeholders, presented at national and international conferences, and published in open-access peer-reviewed journals.

Original languageEnglish
Article numbere111826
Number of pages9
JournalBMJ Open
Volume16
Issue number2
Early online date12 Feb 2026
DOIs
Publication statusPublished - 12 Feb 2026

Data Availability Statement

The data collected during this study cannot be shared
publicly for the privacy of individuals that participate in
the study. The data may be shared on reasonable request
to the corresponding author

Funding

This work was supported by the NIHR, grant number AI_AWARD02549. GM, HM and PM’s time is supported by the National Institute for Health and Care Research Applied Research Collaboration West (NIHR ARC West). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Keywords

  • Artificial Intelligence
  • Computed tomography
  • Health Care Costs
  • Pulmonary Disease
  • Thromboembolism

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Artificial intelligence to improve the detection and risk stratification of acute pulmonary embolism (AID-PE): protocol for a pragmatic quasi-experimental comparator study'. Together they form a unique fingerprint.

Cite this